Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On October 1, 2021, the Board of Directors (the "Board") of NextCure, Inc. (the
"Company"), following the recommendation of the nominating and corporate
governance committee of the Board, elected Anne Borgman, M.D., and Ellen Feigal,
M.D., to the Board. Dr. Borgman will serve as a Class I member of the Board with
a term expiring at the Company's 2023 annual meeting of stockholders, and Dr.
Feigal will serve as Class II member of the Board with a term expiring at the
Company's 2024 annual meeting of stockholders and until their successors are
duly elected and qualified or their earlier resignation, retirement, or removal.
Dr. Borgman has been appointed as a member of the Nominating and Governance
Committee of the Board. Dr. Feigal has been appointed as a member of the
Compensation Committee of the Board. Both Drs. Borgman and Feigal have been
determined to be independent directors.
Dr. Borgman has served as Vice President and Global Therapeutic Area Lead,
Hematology-Oncology of Jazz Pharmaceuticals plc, a global biopharmaceutical
company, since 2019. Prior to that, she served as Vice President, Clinical
Research & Development at Exelixis Biopharmaceuticals, Inc. from 2012 to 2019.
Dr. Borgman completed her clinical and research fellowship at the University of
California, Los Angeles, Section of Pediatric Hematology Oncology and Bone
Marrow Transplant, and prior to that completed her pediatric residency at Baylor
College of Medicine/Texas Children's Hospital. Dr. Borgman received her Bachelor
of Science in Biochemistry from the University of Illinois and received her M.D.
from the Loyola University of Chicago Stritch School of Medicine. Dr. Borgman is
licensed to practice medicine in the states of California and Illinois. She
currently holds an adjunct faculty member position at Stanford University School
of Medicine, Department of Pediatrics, Division of Hematology, Oncology, Stem
Cell, Transplantation, and Cancer Biology and is a clinical associate at the
University of Chicago, Department of Pediatric Oncology and Stem Cell Research.
Dr. Feigal has served as a Partner and Head of the Biologics Practice at NDA
Partners LLC since 2014. NDA Partners is part of ProPharma Group, a life
sciences management consulting and contract development organization. She
currently serves as a board member for Xencor, Inc. Dr. Feigal was formerly
Senior Vice President of Research and Development at the California Institute
for Regenerative Medicine; Executive Medical Director, Global Development, at
Amgen; and Chief Medical Officer at Insys Therapeutics. She was a Founding
Director of the American Course on Drug Development and Regulatory Sciences at
the University of California, San Francisco (UCSF). Prior to UCSF, Dr. Feigal
was Director of Medical Devices and Imaging at the Critical Path Institute and
Vice President of Clinical Sciences at the Translational Genomics Research
Institute. Dr. Feigal received her M.D. from the University of California, Davis
and completed an internal medicine residency at Stanford University and a
hematology/oncology fellowship at University of California, San Francisco, and
currently serves as an adjunct professor at Arizona State University Sandra Day
O'Connor College of Law.
Drs. Borgman and Feigal will be compensated for their service on the Board in
accordance with the Company's Non-Employee Director Compensation Program as
described in the Company's definitive proxy statement filed on April 29, 2021.
Additionally, the Company entered into a customary indemnification agreement
with Drs. Borgman and Feigal in connection with their appointments to the Board.
Item 7.01 Regulation FD Disclosure.
On October 4, 2021, the Company issued a press release announcing Dr. Borgman
and Dr. Feigal's appointments to the Board. A copy of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1
Item 9.01. Financial Statements and Exhibits.
Exhibit
No. Description
99.1 Press release of NextCure, Inc. dated October 4, 2021.
104 Coverage Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses
NEXTCURE, INC. 
